Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. by Parodi, Maurizio B et al.
Parodi, MB; Virgili, G; Evans, JR (2009) Laser treatment of drusen
to prevent progression to advanced age-related macular degeneration.
Cochrane Database of Systematic Reviews (3). ISSN 1469-493X DOI:
10.1002/14651858.CD006537.pub2
Downloaded from: http://researchonline.lshtm.ac.uk/5027/
DOI: 10.1002/14651858.CD006537.pub2
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the author(s)
Laser treatment of drusen to prevent progression to
advanced age-related macular degeneration (Review)
Parodi MB, Virgili G, Evans JR
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2009, Issue 3
http://www.thecochranelibrary.com
Laser treatment of drusen to prevent progression to advanced age-related macular degeneration (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
5BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Figure 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
20DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
42DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Photocoagulation versus control, Outcome 1 Development of CNV. . . . . . . . 43
Analysis 1.2. Comparison 1 Photocoagulation versus control, Outcome 2 Development of CNV: sensitivity analysis
assuming moderate correlation (0.5) for bilateral studies. . . . . . . . . . . . . . . . . . . . 44
Analysis 1.3. Comparison 1 Photocoagulation versus control, Outcome 3 Development of geographic atrophy. . . 45
Analysis 1.4. Comparison 1 Photocoagulation versus control, Outcome 4 Visual loss of 2 to 3+ lines. . . . . . . 46
Analysis 1.5. Comparison 1 Photocoagulation versus control, Outcome 5 Loss of 0.3 or more log units of contrast sensitivity
at 2 years. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Analysis 1.6. Comparison 1 Photocoagulation versus control, Outcome 6 Reading speed (words/minute). . . . . 47
Analysis 1.7. Comparison 1 Photocoagulation versus control, Outcome 7 Drusen reduction. . . . . . . . . . 48
48ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
50APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
54DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
54DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
54INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iLaser treatment of drusen to prevent progression to advanced age-related macular degeneration (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Laser treatment of drusen to prevent progression to
advanced age-related macular degeneration
Maurizio B Parodi1, Gianni Virgili2, Jennifer R Evans3
1Department of Ophthalmology, University of Udine, Udine, Italy. 2Department of Neuro-Oto-Ophthalmological Surgical Sciences,
Eye Clinic, University of Florence, Florence, Italy. 3Cochrane Eyes and Vision Group, ICEH, London School of Hygiene & Tropical
Medicine, London, UK
Contact address: Maurizio B Parodi, Department of Ophthalmology, University of Udine, Piazzale Santa Maria della Misericordia,
Udine, 33100, Italy. maubp@yahoo.it.
Editorial group: Cochrane Eyes and Vision Group.
Publication status and date: New, published in Issue 3, 2009.
Review content assessed as up-to-date: 13 November 2008.
Citation: Parodi MB, Virgili G, Evans JR. Laser treatment of drusen to prevent progression to advanced age-related macular degen-
eration. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD006537. DOI: 10.1002/14651858.CD006537.pub2.
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Drusen are amorphous yellowish deposits beneath the sensory retina. People with drusen, particularly large drusen, are at higher risk
of developing age-related macular degeneration (AMD). The most common complication in AMD is choroidal neovascularisation
(CNV), the growth of new blood vessels in the centre of the macula. The risk of CNV is higher among patients who are already affected
by CNV in one eye.
It has been observed clinically that laser photocoagulation of drusen leads to their disappearance and may prevent the occurrence of
advanced disease (CNV or geographic atrophy) associated with visual loss.
Objectives
To examine the effectiveness and adverse effects of laser photocoagulation of drusen in AMD.
Search methods
We searched CENTRAL, MEDLINE and EMBASE on 14 November 2008.
Selection criteria
Randomised controlled trials (RCTs) of laser treatment of drusen in AMD in which laser treatment had been compared with no
intervention or sham treatment. Two types of trials were included. Some trials studied one eye of each patient (unilateral studies); other
studies recruited patients with bilateral drusen and randomised one eye to photocoagulation or control and the fellow eye to the other
group.
Data collection and analysis
Two review authors independently selected studies and extracted data. We pooled data from unilateral and bilateral studies using a
random-effects model. For the bilateral studies, we estimated the within-patient correlation coefficient from one study and assumed it
was valid for the others.
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Main results
We found nine studies which randomised 2216 people: four unilateral trials, three bilateral trials and two trials that included both a
unilateral and a bilateral study arm.
Overall, the studies were of moderate quality. Only half of the trials reported adequate allocation sequence generation, allocation
concealment and masking of visual acuity outcome assessors.
Although two (of the nine) studies reported significant drusen disappearance at two years, photocoagulation did not appear to affect
the development of CNV at two years follow up (nine studies, 1767 people followed up, odds ratio (OR) 1.04, 95% CI 0.71 to 1.51)
or the loss of three or more lines of visual acuity (six studies, 1628 people followed up, OR 1.17, 95% CI 0.75 to 1.82).
Authors’ conclusions
The trials included in this review confirm the clinical observation that laser photocoagulation of drusen leads to their disappearance.
However, there is no evidence that this subsequently results in a reduction in the risk of developing CNV, geographic atrophy or visual
acuity loss.
P L A I N L A N G U A G E S U M M A R Y
Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Drusen are amorphous yellowish deposits beneath the sensory retina. People with drusen, particularly extensive large drusen, are
at higher risk of developing age-related macular degeneration (AMD). The most common complications in AMD are the growth
of new blood vessels in the centre of the macula (choroidal neovascularisation or CNV also known as ’wet AMD’) and loss of
photoreceptors (geographic atrophy). It has been observed clinically that laser photocoagulation of drusen leads to their disappearance.
Laser photocoagulation of drusen has thus been proposed as a way to prevent the development of CNV and geographic atrophy. This
review included data from nine trials of moderate quality. These studies confirmed the clinical observation that laser photocoagulation
of drusen leads to their disappearance. However, there was no evidence that laser photocoagulation of drusen reduced the risk of
developing CNV, geographic atrophy or visual acuity loss.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Outcomes at two years Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Photocoagulation
Development of CNV 78 per 1000 86 per 1000
(60 to 121)
OR 1.04
(0.71 to 1.51)
1767
(9)
⊕⊕⊕©
moderate1
Low risk population (patients with bilateral drusen)
50 per 1000 55 per 1000
(38 to 79)
HIgh risk population (patients with CNV in the fellow
eye)
250 per 1000 270 per 1000
(202 to 352)
Development of geo-
graphic atrophy
88 per 1000 155 per 1000
(28 to 562)
OR 1.30
(0.38 to 4.51)
66
(1)
⊕⊕©©
low2
Visual loss of 2-3+ lines
of visual acuity
142 per 1000 110 per 1000
(82 to 147)
OR 0.88
(0.67 to 1.14)
1628 (6) ⊕⊕⊕©
moderate3
Loss of 0.3 log units or
more of contrast sensi-
tivity
119 per 1000 100 per 1000
(26 to 309)
OR 0.82
(0.20 to 3.31)
82
(1)
⊕⊕
low2
Reading speed in words/
minute
The mean reading speed
in words/minute in the
control groups was
100 words/minute
The mean reading speed
in words/minute in the in-
tervention groups was
12.5 lower
(7.2 lower to 32.2 higher)
44
(1)
⊕⊕
low2
3
L
a
se
r
tre
a
tm
e
n
t
o
f
d
ru
se
n
to
p
re
v
e
n
t
p
ro
g
re
ssio
n
to
a
d
v
a
n
c
e
d
a
g
e
-re
la
te
d
m
a
c
u
la
r
d
e
g
e
n
e
ra
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
0
9
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Drusen reduction Medium risk population OR 10.72
(3.84 to 29.97
195
(2)
⊕⊕⊕⊕
high4,5
235 per 1000 767 per 1000
(541 to 902)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Allocation sequence generation and allocation concealment and masking of visual acuity outcome assessors was achieved in half or
less of them. Risk of bias from incomplete outcome data was unclear in one study and high in two studies, but sensitivity analyses
did not suggest meaningful changes of pooled ORs (see Figure 5 and Figure 6). Other quality items were not a problem.
2Small study yielding wide 95% confidence intervals.
3Visual acuity examiners were masked in less than half of studies.
4The two studies included in this analysis have low risk of bias.
5Estimates are heterogenous but they both suggest a strong effect.
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B A C K G R O U N D
Description of the condition
Age-related macular degeneration (AMD) is the leading cause
of vision loss in industrialised countries (Klein 2004; Vingerling
1996). Early AMD is characterised by focal or diffuse deposit-
ing of extracellular material between the retinal pigment epithe-
lium and Bruch’s membrane, forming drusen or basal laminar de-
posits respectively (Bressler 1994; Sarks 1999; Young 1987). This
process is associated with progressive degeneration of retinal pig-
ment epithelium and photoreceptor cells (Guidry 2002; Phipps
2003; Young 1987). Advanced AMD is characterised by the de-
velopment of geographic atrophy (characterising the non-exuda-
tive AMD form) or choroidal neovascularisation (characterising
the exudative AMD). When the fovea, which represents the centre
of vision, is involved by atrophic or exudative manifestations of
AMD a severe visual loss results.
Advanced AMD was found to have a prevalence that increases
markedly with age (EDPRG; Owen 2003). In the US, advanced
AMD prevalence is 3.5% to 4% at 75 to 79 years among white
males and females respectively (EDPRG). Based on a systematic
review ofUK studies,Owen 2003 reported that there were approx-
imately 214,000 people (95% CI 151,000 to 310,000) with vi-
sual impairment caused by AMD, and this is estimated to become
239,000 in 2011. In this study, the ratio of neovascular AMD to
geographic atrophy was about 2:1, such as in Smith 2001.
Drusen results from deposition of the photoreceptors debris,
which are composed of lipofuscin and membranous deposits.
Drusen appear when sufficient material has been deposited, clin-
ically characterised by amorphous yellowish deposits beneath the
sensory retina. Four main types of drusen can be detected in
the retina. Hard drusen are discrete, yellow, nodular deposits,
smaller than 50microns in diameter. Basal laminar drusen are tiny,
whitish, multiple deposits with a ’starry night’ appearance. Soft
drusen are yellowish deposits with poorly defined margins, tend-
ing to coalesce, and are usually larger than 50 microns. Crystalline
drusen are discrete, calcific, refractile deposits. Drusen character-
istics associated with a high risk of progression to exudative AMD
(high-risk drusen) include: soft drusen, more than five, larger size
(greater than 63 microns), drusen confluence and associated hy-
perpigmentation.
The cumulative incidence of new exudative or atrophic lesions in
eyes initially free of advanced AMD has been estimated as 8.6%
at one year, 16.4% at two years and 23.5% at three years (Holz
1994). Focusing on the choroidal neovascularisation (CNV) in-
cidence, the results of a prospective investigation of patients with
exudative manifestation in one eye and drusen in the fellow eye has
shown that the risk of developing CNV peaks at four years, dissi-
pating thereafter, whereas there is a slightly increased incidence of
geographic atrophy in the longer-term (Sarraf 1999). Moreover,
the five-year risk of CNV occurrence in the fellow eye of patients
who have already experienced CNV in the first eye, varies from
7% to 87% depending on the coexistence of four main risk factors
(presence of five or more drusen, focal hyperpigmentation, one or
more large drusen and systemic hypertension) (MPSG 1997).
Drusen can spontaneously disappear in patients with AMD, gen-
erally leaving atrophic lesions. More specifically, the Waterman
study has reported that disappearance of large drusen occurred
in 16 (34%) of 47 participants in a five-year longitudinal study
(Bressler 1995).
Description of the intervention
Laser treatment is based on the release of a powerful beam of light
which, combined with ophthalmic equipment and lenses, can be
precisely focused on the retina to treat some diseases. The laser
energy causes a certain amount of controlled damage to the tissues
in order to obtain the desired effect. Small laser burns are usually
employed to obliterate or destroy abnormal blood vessels or other
lesions in the eye.
Several observers noted that laser application can lead to drusen
being resorbed in the macular area (Cleasby 1979; Gass 1973;
Gross-Jendroska 1998; Wetzig 1994). Owing to the risk of vision
loss associated with the presence of high-risk drusen, laser applica-
tion was proposed as an intervention to prevent progression to ad-
vanced AMD. Laser burns are applied to the retina, either directly
to the drusen or following predefined patterns. Argon, krypton,
dye or diode lasers have been used with varying levels of energy
(achieving from not visible to faint or intense whitish retinal le-
sions). The spot size used varies between 100 to 200 microns and
number of spots from less than 10 to nearly 300.
How the intervention might work
The mechanisms of laser-induced drusen regression are only spec-
ulative. Laser treatment may lead to an increased clearance of de-
bris by choroidal phagocytic cells or macrophages. Alternatively,
laser application may improve egress of drusen material through
a thinner or more permeable Bruch’s membrane, with the conse-
quent reduction of its outflow resistance. Laser effect may mani-
fest by triggering retinal pigment epithelial proliferation leading to
the production and release of cytokines and growth factors, which
may also act on the drusen remote from the site of the laser en-
ergy application (Abdelsalam 1999; Frennesson 1998; Pauleikhoff
1990a; Pauleikhoff 1990b). Histopathologic examinations in an-
imal models have shown that phagocytic cells, probably derived
from choriocapillaris pericytes can remove drusenoid material af-
ter laser photocoagulation (Duvall 1985). Protrusion of choroidal
endothelial cell processes into Bruch’s membrane are enhanced by
laser photocoagulation and may play a part in the clearance of
debris from the Bruch’s membrane (Guymer 2001).
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Why it is important to do this review
Age-relatedmacular degeneration is amajor public health problem
indeveloped economieswhere the life expectancy is greatest (but of
no significance in poorer countries with a life expectancy of under
65). Several investigations about health-related and vision-targeted
features have shown that AMD is associated with decreased quality
of life (Brown 2006; Chakravarthy 2005; Hassell 2006; Maguire
2004; Mangione 1999).
Although people with drusen experience few visual symptoms,
once advanced AMD is present, visual loss is generally irreversible.
It has been shown that patients with drusen who take antioxidant
supplementation are less likely to lose 15 or more letters of visual
acuity over the follow up (AREDS 2001), even though this benefit
was considered modest in people with moderate to severe signs of
the disease (Evans 2006). Antioxidants have not been shown ben-
eficial in the primary prevention of AMD (Chong 2007). Thus,
the identification of a prophylactic treatment able to reduce the
complications related to AMD may be highly beneficial.
Laser treatment of drusen appeared to provide positive results in
observational studies (Cleasby 1979; Gass 1973; Gross-Jendroska
1998; Sigelman 1991; Wetzig 1994). A systematic review is nec-
essary to ensure that all the evidence on this intervention is con-
sidered objectively. People with AMD and their caregivers need to
have recommendations as to the possible benefits or harms of this
intervention.
O B J E C T I V E S
The aim of the review is to examine the effectiveness and adverse
effects of laser photocoagulation of drusen in AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs) of laser
treatment of drusen in AMD.
Types of participants
Participants in the trials were people with retinal drusen associated
with AMD in one or both eyes.
Types of interventions
We included trials in which laser treatment for retinal drusen was
compared with no intervention or sham treatment. A variety of
different laser sources and photocoagulation techniques were con-
sidered.
Types of outcome measures
Primary outcomes
The primary outcome measure was progression of AMD as mea-
sured by the development of CNV or geographic atrophy.
Secondary outcomes
Secondary outcomes included:
• loss of visual acuity (LogMAR values);
• changes in contrast sensitivity;
• drusen reduction;
• changes in reading ability;
• vision-related quality of life.
Visual acuity is generally measured by means of a standard chart,
the ETDRS (Early Treatment of Diabetic Retinopathy Study)
chart and scored in letters. There are five letters per line in this
chart. Both dichotomous outcomes, such as moderate (3 lines or
15 ETDRS letters) and severe (6 lines or 30 ETDRS letters) visual
loss and continuous measures (mean visual acuity) were extracted
when possible. Whenever no ETDRS values were used, visual acu-
ity was converted to LogMAR (logarithm of the Minimum Angle
of Resolution) for pooling data.
Contrast sensitivity is generally measured with the Pelli-Robson
chart. Scores are collected in letters or as logarithm of contrast sen-
sitivity. The latter was used for pooling data when feasible. Both
continuous and dichotomous measures were extracted if possi-
ble. For dichotomous data, the proportion of participants with a
change of at least 0.3 or 0.6 log-units, corresponding to a two-fold
or a four-fold change respectively, was recorded.
In the protocol, drusen reduction was planned to be evaluated
considering the number of eyes showing at least a 50% reduc-
tion of drusen area from the baseline aspect. However, data were
sparsely reported and therefore we modified the protocol to allow
an extraction based on the investigators’ definition.
Reading ability measures were converted to LogMAR for reading
acuity, whereas reading speed was considered as the logarithm of
the number of words read in a minute.
Timing of outcome assessment
We assessed outcomes at 24 months, where data were available.
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Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vi-
sion Group Trials Register) (The Cochrane Library Issue 4, 2008),
MEDLINE (January 1950 to November 2008) and EMBASE
(January 1980 to November 2008). There were no language or
date restrictions in the search for trials. The electronic databases
were last searched on 14 November 2008.
See Appendices for details of search strategies for CENTRAL (
Appendix 1), MEDLINE (Appendix 2) and EMBASE (Appendix
3).
Searching other resources
We searched the reference lists of retrieved articles for details of
further relevant studies. We did not handsearch journals or con-
ference proceedings specifically for this review.
Data collection and analysis
Selection of studies
Two authors independently assessed the titles and abstracts result-
ing from the electronic searches for inclusion. We obtained copies
of all relevant or potentially relevant trials and assessed these ac-
cording to the ’Criteria for considering studies for this review’.
The authors were not masked as to the names of authors, institu-
tions, journal of publication or results when making their assess-
ments. We resolved disagreements about whether a trial should be
included by discussion and consensus. In cases where additional
information was needed before a decision was made whether to
include a trial, we obtained this information by contacting the
authors.
Data extraction and management
Information about themethods used in the trial was recorded on a
form including details of participants, details of intervention, out-
comes and other information. Two review authors independently
extracted the data for the primary outcomes, secondary outcomes
and adverse effects onto paper forms. Since the double-entry fa-
cility is no longer available in RevMan 5.0, one review author ex-
tracted data and entered them into RevMan 5.0 (RevMan 2008)
and another review author checked the entries for errors and in-
consistencies.
Assessment of risk of bias in included studies
Two review authors independently assessed the included trials
for bias according to the methods described in Chapter 8 of
the Cochrane Handbook for Systematic Reviews of Interventions 5.0
(Higgins 2008a). With the update of review management soft-
ware, we assessed risk of bias using the tool set out in the Hand-
book.
1. Sequence generation: the method used to generate the
allocation sequence, to assess whether it should have produced
comparable groups.
2. Allocation concealment: the method used to conceal the
allocation sequence, to determine whether intervention
allocations could have been foreseen in advance of, or during,
enrolment.
3. Masking of personnel and outcome assessors: the
assessments were made for each main class of outcomes (i.e.
anatomic versus functional outcomes) and we considered
whether all measures used, if any, to mask study personnel from
knowledge of which intervention a participant received were
adequate.
4. Incomplete outcome data: the assessments were made for
each main class of outcomes (i.e. anatomic versus functional
outcomes) when possible and were based on the description of
the completeness of outcome data, including attrition and
exclusions from the analysis and their causes, if they were
reported.
5. Selective outcome reporting: the possibility of selective
outcome reporting, such as found when some measures were
obtained, as declared in the methods section or in protocols, but
not reported in the results section.
The following grading was used:
• Low risk of bias: plausible bias unlikely to seriously alter the
results.
• Unclear risk of bias: plausible bias that raises some doubt
about the results.
• High risk of bias: plausible bias that seriously weakens
confidence in the results.
If the information available in the published trial reports was in-
adequate to assess any of the above items of the risk of bias as-
sessment, we contacted the trial authors for clarification. If they
did not respond within a reasonable period of time, we classified
the trial based on the available information. When studies did not
report any concealment approach, adequacy was considered to be
unclear. We also assessed the impact of any assumptions made in
this regard in a sensitivity analysis.
We considered a trial to have conducted an intention-to-treat anal-
ysis only if it included all participants who were randomised in-
cluding those randomised but not treated and excluded after ran-
domisation for other reasons.
Measures of treatment effect
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We evaluated development of CNV and geographic atrophy on
the basis of the percentage of their occurrence over the follow up.
We assessed visual acuity loss taking into consideration the loss of
3 or more lines of visual acuity, which corresponds to a doubling
of the visual angle if visual acuity is measured using a logMAR
chart.
We planned to evaluate drusen reduction considering the number
of eyes showing at least a 50% reduction of drusen area from the
baseline aspect.However, datawere sparsely reported and therefore
we modified the protocol to allow an extraction based on the
investigators’ definition.
Dichotomous data
Dichotomous data included, for example, progression of CNV or
geographic atrophy, or loss of 3 or more lines of visual acuity. In
the protocol we stated that we would have used the risk ratio or
relative risk as our preferred measure of effect since we anticipated
that the event rate would be greater than 10%. We actually found
that the event rate was lower than this threshold in bilateral stud-
ies. Furthermore, to be able to manage data from unilateral and
bilateral studies, we had to manipulate them using formulas pro-
posed by Elbourne 2002, which only apply to odds ratios. Little
difference is expected between risk ratios and odd ratios in this
review, since the crude event rate was less than 10% in bilateral
studies and less than 25% in unilateral studies, and also because
the pooled odds ratio was close to 1.
Continuous data
Continuous data included, for example, reading speed. We used
the weightedmean difference, unless the outcomes weremeasured
on different scales in which case we used the standardised mean
difference as the measure of effect.
Unit of analysis issues
Some trials identified a ’study eye’ and randomised participants
to treatment group. Other trials randomised the eye to treatment
and compared with the other eye in the same person. We were
careful to consider these trials separately at the data collection and
extraction stage.
We did two sets of analyses for the primary outcome ’development
of CNV’. Firstly we pooled all the data ignoring the fact that the
data from the bilateral studies were not independent. We then did
a sensitivity analysis assuming an intra-class correlation coefficient
(ICC) of 0.5 for the development of CNV and 0.22 for visual
acuity loss. We adjusted the standard errors using the methods
of Higgins 2008b and Elbourne 2002. See Appendix 4 for more
details.
We used the generic inverse variance facility in RevMan to enter
the data for the sensitivity analysis.
Dealing with missing data
In the event that data were missing we contacted the authors of
the studies in an attempt to obtain more information. On the
basis of the data we could collect, we first did an available case
analysis. We recorded the amount of missing data in the included
studies as shown in Table 1. At the time the protocol for this review
was prepared we planned that if missing data should prove to be
a problem in the constituent studies, we would consider doing
a sensitivity analysis considering outcome in the people lost to
follow up as either ’all OK’ or ’all not OK’ to see the range within
which the true result might lie. This did not prove necessary at
this stage. According to further guidance available in section 8
of the current version of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2008a), missing outcome data is
not a problem if loss to follow up is both balanced in the study
arms of parallel arm studies and causes of loss are documented
and judged to be unrelated to outcome in both study arms. When
these conditions are not satisfied a study can still be at low risk of
bias if the outcome frequency is around 50% and loss to follow
up is below 10% in both arms (Higgins 2008a).
Because our primary outcome was relatively rare in the complete
case analysis in this review, and there were missing data of un-
reported cause, there was potential for bias due to incomplete
outcome data in this review. Thus, we used two approaches to
deal with missing data as explained in Appendix 5. Both ap-
proaches made assumptions regarding informative missing odds
ratio (IMOR): one approach was based on an Excel spreadsheet
prepared by the authors of this review to assess the risk of bias of
each study using a graph and extreme assumptions on missingness;
the other used the Stata 10.2 (StataCorp, College Station, Tx)
users’ written function ’metamiss’ to conduct sensitivity analyses
on primary outcome meta-analysis results by making different as-
sumptions on IMORs across studies according to White 2008.
Assessment of heterogeneity
Before carrying out a meta-analysis we assessed heterogeneity by
examining the characteristics of the study, the forest plot of the
results of the studies and the I2 statistic to assess the presence of
statistical heterogeneity.
Assessment of reporting biases
We planned to assess publication bias (using a funnel plot) if there
were more than 10 trials. However, currently not enough trials are
included in this review to enable this assessment.
Data synthesis
Weplanned toperformameta-analysis if therewere sufficient trials
available without substantial heterogeneity. We used a random-
effects model unless there were three or fewer trials in which case
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a fixed-effect model was used. We compared fixed and random-
effects models to see how robust the results were.
Subgroup analysis and investigation of heterogeneity
If there were sufficient trials, we planned the following subgroup
analyses:
1. type of laser treatment;
2. clinically visible burns versus sub-threshold laser treatment.
Sensitivity analysis
We considered the results of between-person and within-person
trials separately.We had planned to consider the effect of excluding
poor quality studies, if there were sufficient studies. This was not
done.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
The searches identified 111 reports of studies. We obtained full
copies of 31 reports which referred to 10 potentially relevant stud-
ies. We excluded two of these trials mainly because the treat-
ment groups were not randomly allocated (see ’Characteristics of
excluded studies’ table). Overall, nine trials were considered suit-
able for inclusion in the review (see ’Characteristics of included
studies’ table). One study was published in abstract form only and
the investigators supplied unpublished data for inclusion in this
review (Laser to Drusen Study).
Included studies
Types of studies
The study design was different across studies. Three studies in-
cluded one eye of each patient (Frennesson 1995; Laser to Drusen
Study; PTAMD), and will be referred to as ’unilateral’ studies.
Three studies adopted a paired design whereby both eyes of the
participant were included in the study, one eye randomly allocated
to photocoagulation or control and the fellow eye to the other
group (CAPT; Figueroa 1994; Little 1995) and will be referred
to as ’bilateral’ studies. Three more studies included both a uni-
lateral and a bilateral arm (CNVPT; DLS; Olk 1999). However,
CNVPT did not report results from the bilateral study arm except
for the number of patients with a gain of one or more lines of
visual acuity at one year in an early report and therefore data on
this arm could not be extracted.
Types of participants
The nine trials randomised a total of 2216 people. The studies
took place in the USA (CAPT; CNVPT; Laser to Drusen Study;
Little 1995; Olk 1999; PTAMD), Sweden (Frennesson 1995),
UK (DLS), Germany (DLS), Australia (DLS) and Spain (Figueroa
1994).
The mean age of the patients was approximately 70 years. The
majority of participants were women in all studies (range: 54% to
70%).
All studies recruited patients presenting medium (> 63 µm) or
large (> 125µm) drusen with pigmentary changes. CNVPT,DLS
and Figueroa 1994 enrolled patients with bilateral macular drusen
in the bilateral arm and patients with neovascular AMD in one eye
and macular drusen in the fellow eye in a unilateral study. Little
1995, Olk 1999, Frennesson 1995 and CAPT enrolled patients
with macular drusen in both eyes.
Types of interventions
Table 2 gives details of the laser treatment employed in the different
studies. Five studies employed argon laser, two diode laser and
one dye laser. Laser spot size varied from 50 to 200 microns. The
duration of each burn ranged from 0.05 second to 0.1 second. The
number of laser spots included was between 1 and 60. PTAMD
used subthreshold photocoagulation using 810 nm diode laser in
all treated patients. Olk 1999 used subthreshold photocoagulation
in a random subset of treated eyes.
Primary outcomes
Four bilateral studies or study arms (CAPT; DLS; Little 1995;
Olk 1999) and six unilateral studies or study arms (CNVPT;DLS;
Frennesson 1995; Laser to Drusen Study; Olk 1999; PTAMD)
presented data on the outcome ’development of CNV’.
We stated in the protocol that we aimed to obtain data at two years.
However, we used three-year data for two studies that reported the
outcome with more detail at this time point (DLS; Frennesson
1995) and Little 1995 used the last visit at a mean of 3.2 years.
CAPT and Olk 1999 did not report crude data at two years, but
presented survival curves, fromwhich we extracted graphically the
proportion of patients with CNV and atrophy at two years using
the number of eyes followed up in each group to compute standard
errors. Most bilateral studies provided marginal data only, i.e. a
frequency tabulation that ignores the paired nature of data, but we
could extract and use a correlation coefficient from DLS as shown
in Appendix 4.
Among bilateral studies, we could extract paired data on devel-
opment of CNV from Little 1995 but we considered that this
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was too small a study to estimate the correlation coefficient reli-
ably. Marginal data were available from CAPT, but the P value
was obtained from a Cox proportional hazards model, not from
a McNemar Chi2 test, thus we did not use the method shown in
Appendix 4.
There was poor reporting of the primary outcome ’development
of geographic atrophy’. Data from Laser to Drusen Study were
obtained from the authors. Data from survival curves could be
estimated from the unilateral arm of CNVPT; cross-tabulations
were constructed using the number of complete cases who did not
develop CNV because, in the absence of a clear reporting of the
total number of eyes at each step of the survival curve, we consid-
ered that eyes with a neovascular lesion may have complex fundus
changes preventing a precise assessment of geographic atrophy.
Secondary outcomes
Loss of visual acuity was the only secondary outcome which could
be extracted for most studies. Particularly, DLS and CAPT pre-
sented bilateral data and Olk 1999, DLS, PTAMD and CNVPT
presented unilateral data. Most studies provided marginal data,
but we could extract a correlation coefficient from Little 1995 and
DLS and use it as shown in Appendix 4 to obtain correct standard
errors.
Contrast sensitivity and reading ability data were available only in
CNVPT.
Drusen reduction was analysed in most studies. It was possible
to extract data on this outcome from two unilateral studies. For
CNVPT they were extracted graphically from a survival curve us-
ing the number of eyes followed up in each group to generate a
cross-tabulation of the eyes with a 50% or more drusen area reduc-
tion among treated and control eyes. The approximate percent-
ages with apparent drusen reduction was also given in PTAMD
at 18 months; we used the number of patients still followed mi-
nus those who developed CNV as the total number in each group
for generating the 2x2 table. Data on drusen reduction could not
be extracted from the other studies. In fact, CAPT and Little
1995 were bilateral studies but reported marginal data only. Olk
1999 provided pooled data only for unilateral and bilateral cases.
Frennesson 1995 providedmeans and standard deviations but used
Snellen values to compute them, which is incorrect, and data had
a very skewed distribution. Thus, we decided not to use data from
this study. DLS did not report this outcome.
Quality of life data were not available in any study.
Other comparisons
Olk 1999 also compared subthreshold, i.e. yielding non-visible
laser burns, photocoagulation with observation. Marginal data
from the bilateral study arm, but no estimate of the intraindivid-
ual correlation, could be obtained, together with data from the
unilateral study arm.
Excluded studies
We excluded two studies: Sarks 1999 which was a comparative
but non-randomised study and Sigelman 1991 which was a case
report.
Sivagnanavel 2004 is as yet unpublished. We are in contact with
the trialists and plan to include data from this study at a later date.
Risk of bias in included studies
See ’Risk of bias’ tables and Figure 1 and Figure 2.
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Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies. Quality assessment regarding incomplete outcome
data refers to the unilateral study arm only for studies including both unilateral and bilateral arms (DLS; Olk
1999) and to all unilateral studies (CAPT; Frennesson 1995; Laser to Drusen Study). Bias related to
incomplete outcome data does not apply to bilateral studies or study arms because both eyes of the patient
lost to follow up are commonly lost.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
12Laser treatment of drusen to prevent progression to advanced age-related macular degeneration (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Only half of the trials reported adequate methods to generate and
conceal the allocation sequence.
Blinding
Patients were not masked (blinded) since a sham procedure was
never adopted. We acknowledge that it is not possible to mask
outcome assessors to anatomic outcomes because laser scars are
visible around the macula. However, masking of functional out-
come assessors can be achieved in theory, but was rarely so, or
reported as such, in these studies. We think that development of
CNV is a sufficiently objective diagnosis to be classified as having
low risk of bias despite lack of masking of outcome assessors. On
the contrary, vision outcomes such as visual acuity and contrast
sensitivity can easily be measured by a masked assessor, and lack
of masking can introduce bias because the procedure is operator
dependent.
Incomplete outcome data
Table 1 shows events and non-events of complete cases, number
of deaths and number of missing patients in the treatment and
control arms. These data were used to assess the impact of incom-
plete outcome data.
Assessment of risk of bias due to incomplete outcome data
in each study
(Method 1, see Appendix 5 and Figure 3)
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Figure 3. Graphical assessment of the risk of bias due to incomplete outcome data using Method 1 (see
Appendix 5). The minimum and maximum OR change, compared to complete or available cases, is assessed
graphically and subjectively taking into account its 95% CI. The resulting agreed classification is shown in to
classify risk of bias of individual studies regarding the primary outcome of this review.
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Besides data on complete and missing participants, Table 1 also
shows the judgement on risk of bias due to incomplete outcome
data using Method 1, which is also reported in the ’Risk of bias’
table. This judgement is based on the examination of Figure 4,
which presents the minimum and maximum imputed OR, to-
gether with complete case OR obtained from the primary analysis,
computed by means of Method 1 (see Appendix 5). The unilat-
eral arm of DLS and Figueroa 1994 had no missing data; thus the
risk of bias was low and there was no need of imputation. Little
1995 was classified as unclear since only mean follow up was re-
ported and data were used as such for imputation usingMethod 2.
For all other studies, except Frennesson 1995, the minimum and
maximum imputed OR were obtained assuming twice the odds of
CNV among missing patients (OR = 2) and, respectively, values
of 0.5 and 2 of the relative OR for treatment effect among miss-
ing versus complete cases. Frennesson 1995 had no events among
treated patients versus four among controls. Thus, 0.5 was added
to all cells of complete cases. The extremeOR values for this study
were obtained assuming contemporary extreme values of the two
probability modifiers (0.5 - 0.5 and 2 - 2 event occurrence OR
and relative treatment OR due to missingness).
Figure 4. Forest plot of comparison: 1 Photocoagulation vs. control, outcome: 1.1 Development of CNV
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Based on the inspection of additional Figure 4, we classified Olk
1999 and PTAMD as having high risk of bias due to incomplete
outcome data, and the other studies with missing data as having
low risk of bias. We considered the subjective graphical assessment
of both the point estimate and the 95% CI coverage for this clas-
sification. We took into account only large changes because these
were extreme scenarios, especially regarding the assumption of a
two-fold treatment OR modification, considering that complete
case meta-analysis yielded a point estimate of 1.04.
Assessment of overall risk of bias in the meta-analysis results
using ’metamiss’
(Method 2, see Appendix 5; Figure 5; Figure 6)
Figure 5. Sensitivity meta-analysis assuming random uncorrelated opposite IMORs for treatment and
controls 1/2 and 2 (prior logIMOR standard deviation 1, uncorrelated IMORs between treatment and control
groups (Method 2, see Appendix 5)).
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Figure 6. Sensitivity meta-analysis assuming random uncorrelated opposite IMORs for treatment and
controls 2 and 1/2, prior logIMOR standard deviation 1, uncorrelated IMORs between treatment and control
groups (Method 2, see Appendix 5)
Additional Figure 7 and Figure 8 present sensitivity meta-analyses
based on random uncorrelated opposite IMORs for treatment and
controls (1/2 and 2; 2 and 1/2): the pooled ORs were 0.92 (95%
CI 0.68 to 1.23, I2 = 19.1%) and 1.10 (95% CI 0.82 to 1.48, I
2 = 18.6%) respectively. Under extreme IMOR assumptions, nei-
ther meta-analyses suggests very different estimates compared to
our primary analysis. As with Method 1, Olk 1999 and PTAMD
showed the larger changes by missing imputation due to a larger
number of missing patients.
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Figure 7. Forest plot of comparison: 1 Photocoagulation vs. control, outcome: 1.5 Development of CNV:
sensitivity analysis assuming moderate correlation (0.5) for bilateral studies.
Figure 8. Forest plot of comparison: 1 Photocoagulation vs. control, outcome: 1.2 Visual loss of 2-3+ lines
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Selective reporting
Most studies reported the development of CNV and visual acuity
which are the key outcomes in this study so selective reporting was
not considered to be a problem in this review.
Other potential sources of bias
One trial (DLS) was stopped early because an interim analysis
suggested an harmful effect of photocoagulation.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table: photocoagulation of drusen vs control
Primary outcome: development of choroidal
neovascularisation
Pooling the results of five bilateral studies and six unilateral studies,
as seen in Figure 4, the development of CNV at two years was not
statistically different between photocoagulation and observation
but favoured observation (OR 1.04, 95% confidence interval (CI)
0.71 to 1.51).
A sensitivity analysis assuming moderate correlation (0.5) of the
outcomewithin individuals increased the heterogeneity of bilateral
studies to an I2 value of 60%, suggesting that a meta-analysis of
these studies may not be appropriate, also given the fact that effect
estimates of individual studies were in opposite directions. This
is shown in Figure 7 for completeness as well as to show that the
conclusions would not change if such a meta-analysis were carried
out.
Primary outcome: development of geographic
atrophy
As reported above, data on the development of atrophy could be
extracted from only two small studies (CNVPT; Laser to Drusen
Study). No benefit or harm using photocoagulation could be
demonstrated regarding this outcome (OR 1.30, 95% CI 0.38 to
4.51).
One bilateral study presented marginal data on this outcome.
Specifically, CAPT reported that 1.9% treated eyes compared to
1.4% control eyes of 1008 individuals developed atrophy at two
years, but due to the paired nature we could not extract and anal-
yse these data.
Secondary outcome: visual acuity
Two bilateral studies and five unilateral studies (Figure 8) allowed
the extraction of data on the risk of visual loss of 3 or more lines of
visual acuity at two years (a value of 2 or more lines was available
in Olk 1999). No benefit or harm with photocoagulation could
be demonstrated in this analysis (OR 0.88, 95% CI 0.67 to 1.14).
Secondary outcome: contrast sensitivity
Data on contrast threshold were obtained from the authors of
the Laser to Drusen Study. There was a large uncertainty of the
estimates (Analysis 1.5) and no effect of photocoagulation could
be demonstrated.
CAPT also reported on this outcome, but this was a paired study
and the data could not be analysed since an estimate of the cor-
relation coefficient was not obtained. The authors reported mar-
ginal data at five years, which indicated that 212 (23.9%) of 888
treated eyes and 182 (20.5%) of 887 observed eyes required twice
as much contrast (corresponding to a loss of 0.3 log 10 units or
more of contrast sensitivity) to read letters.
Secondary outcome: reading ability
Data on reading speed were obtained by the authors of the Laser
to Drusen Study for about 50% of the patients included in this
small study. No statistically significant difference between photo-
coagulation and observation was found (Analysis 1.6).
CAPT also reported marginal data on reading ability expressed
as critical print size, i.e. the character prints size below which a
patient’s reading speed slows down. The authors reportedmarginal
data at five years, which indicated that 260 (29.6%) of 879 treated
eyes and 249 (28.4%) of 878 observed eyes required a print size
twice as large (3 LogMAR lines) or could not read even the largest
print size.
Secondary outcome: drusen reduction
Data on drusen reduction as defined by the investigators could be
extracted from two unilateral studies at approximately two years
(Figure 9).CNVPT found that 25/30 treated eyes compared to 14/
31 control eyes had a 50%ormore drusen reduction at 18months,
corresponding to an OR in favour of treatment of 6.07 (95%
CI 1.84 to 20.01). PTAMD reported that an apparent drusen
reduction was observed in 50% of treated eyes compared to less
than 1% of control eyes (we conservatively assumed a risk of 1%
among controls); these data generate an OR of 55.38 (95% CI
7.3 to 420.27).These estimates are heterogeneous (I2 = 71%),
possibly due todifferent outcomedefinitions, andwere not pooled.
Nonetheless, they point in the same direction and indicate that
drusen area decreases in treated eyes.
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Figure 9. Forest plot of comparison: 1 Photocoagulation vs. control, outcome: 1.4 Drusen reduction.
Among bilateral studies, others presented marginal data suggest-
ing that photocoagulation causes drusen resorption, but we could
not extract these data since an estimate of the within-patient cor-
relation was not obtained. Specifically, CAPT found that 34.3%
treated eyes versus 8.6% control eyes of 1008 individuals had a
50% drusen reduction at two years. Figueroa 1994 reported that
29/30 treated eyes versus 2/30 control eyes were found to have
drusen reduction, on average after three months. Little 1995 re-
ported that 17/27 treated eyes had drusen resorption by sixmonths
compared to 5/27 observed eyes by one year.
Other studies reported data suggesting drusen disappearance using
photocoagulation compared to observation, but data could not
be extracted for various reasons (means and standard deviations
suggesting skewed data (Frennesson 1995), pooled data from uni-
lateral and bilateral study arms (Olk 1999), or data not available
(DLS)).
Other comparisons
Olk 1999 also compared subthreshold photocoagulation with ob-
servation at two years. In the unilateral study arm they reported
that 4/15 eyes treated with subthreshold photocoagulation versus
7/26 control eyes (OR 1.0, 95% CI 0.2 to 5.0) developed CNV
at one year. In the bilateral study arm the corresponding numbers
were 0/34 and 3/65, but we could not use these data since we did
not have an estimate of within-patient correlation for this outcome
in this comparison.
Considering a visual loss of 2 or more lines, 9/15 treated eyes
versus 10/25 control eyes developed visual loss in the unilateral
study arm (OR 2.2, 95% CI 0.5 to 10.3).
D I S C U S S I O N
Age-related macular degeneration is a disease characterised by an
enormous social burden. The availability of a therapeutic approach
able to reduce the incidence of the major complications, i.e. CNV
and atrophy, would be extremely welcome. Several authors have
recorded that in their experience the use of laser can result in
reabsorption of macular drusen (Cleasby 1979; Figueroa 1994;
Gass 1973; Wetzig 1994). As yet it is unclear whether drusen
reduction can lead to clinical benefits, including improvement or
stabilisation of visual acuity, delayed or reduced CNV or harms
such as the onset of atrophy.
Summary of main results
In preparing this review we identified nine different trials, includ-
ing one unpublished trial, inwhich 2216patientswere randomised
to laser treatment of drusen or observation. These trials confirmed
the clinical observation that laser photocoagulation of drusen was
able to cause their disappearance. However, there was no evidence
that this loss of drusen resulted in any benefit in terms of the de-
velopment of CNV or geographic atrophy or prevention of visual
acuity loss. The results of the present review do not indicate that
the prophylactic laser treatment of drusen is an effective means
for delaying the progression of AMD and preventing visual loss.
However, a clinically relevant benefit or harm cannot be excluded
based on the primary outcomes 95% CI, which were rather wide
(OR 0.71 to 1.51). Among the secondary outcomes, the CI of
the visual loss outcome tended to exclude important harms (OR
upper limit: 1.14 favouring control).
Overall completeness and applicability of
evidence
Some of these trials adopted a paired study design, which rendered
the analysis of the data difficult. Moreover, only a few studies re-
ported data on secondary outcomes, especially contrast sensitivity
and reading ability. Despite these limitations, the studies included
in this review were conducted in different countries and follow up
length was enough to be able to record long-term effects of this
intervention.
Quality of the evidence
Overall, the studies representmoderate quality of evidence because
allocation sequence generation and allocation concealment and
masking of visual acuity outcome assessors was achieved in half
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or less of them. Three studies, accounting for 27% of the weight
in the primary analysis, were of unclear or low quality regarding
incomplete outcome data. However, missing data imputation in
sensitivity meta-analysis did not change our conclusions. Other
quality items were not a problem.
Potential biases in the review process
One peculiar source of bias in this review may be the pooling of
unilateral and bilateral studies based on assumptions about the
statistical correlation of within-patient data. To try to counteract
this potential shortcoming we not only used the information avail-
able from some studies, suggesting very low correlation for the
primary outcome ’occurrence of CNV’, but also used an average
correlation as a sensitivity analysis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Even though drusen area reduction can be achieved through laser
treatment, this review does not suggest that this intervention is as-
sociated with improved outcomes for the patients, based on meta-
analyses of studies which, overall, had a moderate risk of bias.
Implications for research
The results of this review do not encourage the conduct of more
research on photocoagulation directed to drusen in patients with
AMD.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
CAPT
Methods Method of allocation: treatment assignments were generated using a randomly permuted
block method, stratified by clinical centre and using a randomly chosen block size. A
member of the CAPT Co-ordinating Centre reviewed an eligibility checklist with the
local ophthalmologist and clinic co-ordinator during a teleconference before disclosing
which of the two eyes was assigned to laser treatment
Masking: masked visual acuity examiners. Unclear if patients and care providers were
masked. Not reported if anatomic outcomes assessors were masked (i.e. Photograph
ReadingCentre), butmasking is unlikely to be achieved since photocoagulation generates
visible scars
Exclusions after randomisation: none reported
Losses to follow up: through 5 years of follow up, 5891 (97.2%) visits were completed
of the 6061 6-month and annual visits scheduled for surviving CAPT participants. This
percentage was relatively stable over time
Unusual study design: bilateral or paired study, i.e. one eye randomised to treatment or
control and the fellow eye to the other study arm
Participants Country: USA
Number randomised: 1052 patients
Age: mean 71
Sex: 637 females (60.6%)
Inclusion criteria: at least 10 drusen of size 125 micrometres or more within 3000
micrometres of FAZ centre; BCVA: 20/40 or more; 50 year or older
Exclusion criteria: CNV or serous retinal pigment epithelial detachment in either eyes;
geographic atrophy within 500 micron of FAZ centre; any ocular disease that might
affect visual acuity
Interventions Treatment: 60 burns in a grid pattern using a 100 micrometre spot size, 0.1 second
duration and power to achieve a barely visible lesion. The burns were applied within an
annulus between 1500 and 2500 micrometres from the FAZ centre.
Control: observation
Outcomes Primary: loss of 15 letters or more
Secondary: change in VA; change in contrast sensitivity; change in critical print size; in-
cidence of late AMD (CNV, serous pigment epithelial detachment, geographic atrophy)
Notes Since 2001 the patientswere informedof theAREDS results andwere left free to consume
antioxidants
Risk of bias
Item Authors’ judgement Description
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CAPT (Continued)
Adequate sequence generation? Yes Randomly permuted block method used,
stratified by clinical centre and using a ran-
domly chosen block size
Allocation concealment? Yes Eligibility assessed before randomisation
and central allocation by telephone
Blinding?
Development of CNV/geographic atrophy
Yes Unmasked study, but CNV occurrence is
sufficiently objective as a diagnosis to be
considered unbiased
Blinding?
Measurement of vision
Yes Masked visual acuity examiners, unclear if
care providers were masked. Patients can-
not be masked since no sham procedure is
mentioned
Incomplete outcome data addressed?
All outcomes
Yes See Appendix 5 and Figure 3. Through 5
years of followup, 5891 (97.2%) visits were
completed of the 6061 6-month and an-
nual visits scheduled for surviving CAPT
participants. This percentage was relatively
stable over time
Free of selective reporting? Yes Development of CNV and atrophy, as well
as loss of 3 or more lines of visual acuity are
well-defined and relevant outcomes
Free of other bias? Unclear Unclear
CNVPT
Methods BILATERAL: method of allocation: right eye randomly assigned to either laser treatment
or observation. Left eye assigned to alternate treatment
UNILATERAL: random allocation to laser treatment or observation
Stratified by clinical centre and study (bilateral/unilateral) and blocked using a randomly
selected block size. Issued over telephone from central location
Masking: participant: no; provider: unclear; outcome: no for fundus features; yes for
visual acuity
Exclusions after randomisation: not reported.
Losses to follow up: among participants alive at 12 months 57/57 were examined in the
laser group and 58/61 in the observation group. At 2 years 46/57 (80.7%) treated eyes
compared to 47/58 (81%) control eyes were still followed. However, causes of loss to
follow up other than death are not reported
Participants Country: USA 15 clinical centres
BILATERAL: number randomised: 156. Age: average 71. Sex: 61% female
UNILATERAL: number randomised: 120. Age: average age 73. Sex: 63% female in
treatment group; 59% female in control group
Inclusion criteria: aged 50 years plus with colour stereo photographs and a fluorescein
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CNVPT (Continued)
angiogram of both eyes taken within 14 days of enrolment, free of any condition that
would preclude 2 years follow up. No exudative AMD. Study eye: > 10 large drusen (>
63 microns) within 3000 microns of the foveal avascular zone with visual acuity of 20/
40 or better and no evidence of current or past CNV
BILATERAL: no exudative AMD in both eyes
UNILATERAL: no evidence of current or past CNV. Exudative AMD in fellow (non-
study) eye.
Exclusion criteria: evidence of serous pigment epithelial detachment 1 MPS disc area
or more, geographic atrophy within 500 microns of the centre of the foveal avascular
zone, myopia (>= 8 diopters spherical equivalent), previous laser treatment to the retina,
severe non-proliferative or proliferative diabetic retinopathy or diabetic macular oedema,
progressive ocular disease
Interventions Treatment: low-intensity laser treatment. Three different laser treatment protocols: (1)
Laser 20: 20 laser burns, 100 microns in diameter, in a pattern of 3 rows placed between
the 12 and 6 o’clock positions beyond the temporal perimeter of the foveal avascular
zone. The desired intensity of the burns was a grey-white lesion. Direct application of
laser burns to drusen to be avoided. Whenever the area of drusen had not been reduced
by 50% or more at 6 months of enrolment, a second treatment was applied nasal to the
fovea in a mirror image of the first treatment. During the last 6 months of enrolment, a
second laser treatment protocol was adopted that specified 24 laser burns, 100 microns
in diameter in a circular pattern of 2 rows surrounding the macular drusen
Control: observation of fellow eyes
Outcomes Visual acuity (EDTRS); contrast threshold (Pelli Robson); reading ability (MN Read
charts)
Development of CNV, development of geographic atrophy, disappearance of drusen
(stereoscopic colour photographs of the macular and disc of each eye and fluorescein
angiogram)
Notes Enrolment in these pilot studies was suspended after recommendation by the Data
and Safety Monitoring Committee (DSMC) because there was a higher incidence of
CNV within 12 months of study enrolment in laser-treated eyes than in observed eyes,
predominantly in the Fellow Eye Study
Furthermore, data from the bilateral study arm was reported at 12 months but not
thereafter
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Stratified by clinical centre and study (bi-
lateral/unilateral) and blocked using a ran-
domly selected block size
Allocation concealment? Yes Issued over telephone from central location
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CNVPT (Continued)
Blinding?
Development of CNV/geographic atrophy
Yes Unmasked study, but CNV occurrence is
sufficiently objective as a diagnosis to be
considered unbiased
Blinding?
Measurement of vision
No Participant and outcome assessors were
not masked, unclear if care providers were
masked
Incomplete outcome data addressed?
All outcomes
Yes SeeResults, Appendix 5 andFigure 3.UNI-
LATERAL: 81%followed at 2 years in both
study arms; loss to follow up is balanced
but causes of loss are not reported
Free of selective reporting? Yes Development of CNV and atrophy, as well
as loss of 3 or more lines of visual acuity are
well-defined and relevant outcomes
Free of other bias? No Enrolment in these pilot studies was sus-
pended under recommendation by the
Data and Safety Monitoring Committee
(DSMC) because there was a higher inci-
dence of CNV within 12 months of study
enrolment in laser-treated eyes than in ob-
served eyes, predominantly in the Fellow
Eye Study
DLS
Methods Method of allocation: randomisation was conducted with a computerised weighted coin
method in the Research and Development office.The randomisation assignment was
provided by telephone, and the clinic co-ordinator printed the randomisation assign-
ment on the patient’s baseline form. The clinical investigator was then informed of the
randomisation allocation. All study eyes of eligible patients in the UNILATERAL group
were randomised. The study eye was randomised to laser treatment or no laser treatment.
All right eyes of eligible patients in the BILATERAL group were randomised to laser
treatment or no laser treatment; the fellow eye received the alternate treatment
Masking: participant: unclear; provider: unclear, outcome assessor: masked visual acuity
examiner
Exclusions after randomisation: none reported
Losses to follow up: UNITERAL: at 3 years, visual acuity was obtained in 73/92 (80.7%)
laser-treated eyes versus 66/85 (77.6%) control eyes. Development of CNVwas recorded
in 91/92 treated eyes and 85/85 control eyes. BILATERAL: visual acuity obtained in
72/105 patients at 3 years, and CNV development assessed in 103/105 eyes at 3 years
Unusual study design: some patients had both eyes randomised (BILATERAL group)
and within-patient correlation was taken into account
Participants Country: UK
BILATERAL: number randomised: 105. Age: 70.1 (52 to 100). Sex: 31males/ 74 females
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DLS (Continued)
UNILATERAL: number randomised: 177. Age: 72 (54 to 87). Sex: 80 males/ 97 females
Inclusion criteria: drusen with/without focal RPE hyperpigmentation in the study eye
and CNV in the fellow eye; BCVA at least 6/12 (20/40); at least 50 years
Exclusion criteria: geographic atrophy in either eye; any other eye disease able to influence
VA; allergy to fluorescein
Interventions Treatment: argon green/yellow dye laser with 200 micrometre spot size, 0.2 second dura-
tion and the lowest energy to produce a very faint burn; overall 12 burns: 4 burns placed
750 micrometres from FAZ centre (12-3-6-9 o’clock), and 8 burns 1500 micrometres
fromFAZ centre (12, 1.30, 3, 4.30, 6, 7.30, 9. 10.30, 12 o’clock); drusen treated directly
if they were coincident with protocol treatment allocation
Control: observation
Outcomes Proportion of patients who developed CNV; visual acuity
Notes Protocol of treatment revised after 23 months: 12 burns (0.2 sec to 200 micrometre spot
size) placed in circular pattern at 1000 micrometres form FAZ centre
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated method
Allocation concealment? Yes The clinical investigator was informed of
the randomisation allocation by the Co-or-
dinator by telephone after eligibility was as-
sessed
Blinding?
Development of CNV/geographic atrophy
Yes Unmasked study, but CNV occurrence is
sufficiently objective as a diagnosis to be
considered unbiased
Blinding?
Measurement of vision
Yes Masked visual acuity examiners. Patients
cannot be masked since no sham procedure
is mentioned
Incomplete outcome data addressed?
All outcomes
Yes See Results, Appendix 5 and Figure 3.
Losses to follow up are balanced but causes
are not reported; no risk of bias given the
paired study design for the BILATERAL
study arm
Free of selective reporting? Yes Development of CNV and atrophy, as well
as loss of 3 or more lines of visual acuity are
well-defined and relevant outcomes
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DLS (Continued)
Free of other bias? No The trial was stopped early after an interim
analysis suggested that laser treatment in-
duced CNV in treated eyes of patients in
the unilateral group
Figueroa 1994
Methods Method of allocation: not reported.One eye of patients with bilateral drusenwas assigned
to treatment and the other to control
Masking: not reported if participants and providers, but patients cannot be masked since
there is no sham procedure. Visual acuity examiners were masked
Exclusions after randomisation: none reported.
Losses to follow up: since they report on results at last examination (mean follow up is
3 years), assessing the impact of loss to follow up is difficult
Unusual study design: paired or bilateral study; authors also report on a parallel case
series of patients with CNV in one eye who were all treated in the fellow eye
Participants Country: Spain
Number randomised: 30
Age: 69 (range: 62 to 74)
Inclusion criteria: AMD with large confluent soft drusen involving the fovea
Exclusion criteria: not specified
Interventions Treatment: green argon laser; 0.1 mW, 0.1 sec, 100 micrometre spot; laser spot on drusen
in the temporal fovea, or grid pattern if drusen larger than 300 micrometre
Control: observation
Duration: 3 years on average (1.5 to 5 years)
Outcomes Occurrence of CNV, reduction of drusen, visual acuity
Notes Drusen resolution possible also for drusen located far from the laser application
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Not reported
Blinding?
Development of CNV/geographic atrophy
Yes Unmasked study, but CNV occurrence is
sufficiently objective as a diagnosis to be
considered unbiased
Blinding?
Measurement of vision
Yes Masked visual examiner
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Figueroa 1994 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes See Results, Appendix 5 and Figure 3.Data
at mean follow up are reported. Since 12
out of 30 patients were followed for less
than 3 years, it is difficult to assess the im-
pact of this type of reporting
Free of selective reporting? Unclear Development of CNV and atrophy, as well
as loss of 3 or more lines of visual acuity are
well-defined and relevant outcomes
Free of other bias? Unclear Unclear
Frennesson 1995
Methods Method of allocation: not reported; in 5 patients with both eyes eligible the eye with
better visual acuity was randomised
Masking: participant: unclear; provider: unclear; outcome: unclear
Exclusions after randomisation: none reported
Losses to follow up: 2/19 patients in the treated group vs. 0/19 in the control group lost
to follow up at 3 years
Unusual study design
Participants Country: Sweden
Number randomised: 38
Age: 71.6 (6.5 SD) treated patients; 68.5 (6.2 SD) control patients
Inclusion criteria: soft drusen; visual acuity at least 0.8
Exclusion criteria: CNV, PED, pigmentary clumping, macular atrophy, haemorrhage,
any other eye disorder which could affect VA
Interventions Treatment: argon green laser with 200 micrometre spot size, 0.05 seconds duration,
power to produce a barely visible lesion. Treatment with a temporal horseshoe-shaped
area extending to the vascular arcades, with direct treatment of the drusen.
Control: observation
Duration: 3 to 8 years
Outcomes Anatomic: mean drusen area, development of CNV. Functional: Snellen visual acuity;
colour vision (Farnsworth panel D-15); central visual field (Humphrey 10-2)
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Not reported
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Frennesson 1995 (Continued)
Blinding?
Development of CNV/geographic atrophy
Yes Unmasked study, but CNV occurrence is
sufficiently objective as a diagnosis to be
considered unbiased
Blinding?
Measurement of vision
Unclear Not reported. Patients cannot be masked
since no sham procedure is mentioned
Incomplete outcome data addressed?
All outcomes
Yes See Results, Appendix 5 and Figure 3. 2/
19 (11%) patients in the treated group vs.
0/19 in the control group lost to follow up
at 3 years; causes of loss to follow up not
reported
Free of selective reporting? Yes Development of CNV and atrophy, as well
as loss of 3 or more lines of visual acuity are
well-defined and relevant outcomes
Free of other bias? Unclear Unclear
Laser to Drusen Study
Methods Method of allocation: computer generated randomisation list with randomly selected
block sizes. Allocation groups: observation vs. laser (1:1), laser further divided (1:1) in
temporal vs. nasal and temporal treatment
Masking: participant: unclear; provider: unclear; outcome: unclear
Exclusions after randomisation: none reported
Losses to follow up: 7/47 (15%) of treatment group and 10/52 (19%) of control group
seen at 2 years
Participants Country: USA
Number randomised: 99
Age: range 55 to 84, mean 74 (6.6 SD)
Sex: 69.7% female
Inclusion criteria:
• Large drusen (> 63 microns in diameter) and focal hyperpigmentation, and no
neovascular AMD in one eye only (study eye)
• Evidence of neovascular AMD (CNV, disciform scar, laser scar for CNV) in one
eye only (fellow eye)
• visual acuity 20/40 or better in study eye (other information says 20/50 or better)
• no significant coexisting ocular disorder in study eye
• age 50 years or older
Exclusion criteria:
• history of laser surgery or vitreous surgery in study eye
• low probability of completing 2-year follow-up schedule (poor health, live far
from clinical centre, unwilling to return)
• geographic atrophy within 3000 microns of foveal centre
• other conditions associated with CNV, including pathologic myopia (spherical
equivalent exceeding -8.00 diopters or clinical evidence of lacquer cracks), angioid
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Laser to Drusen Study (Continued)
streaks, histo spots, pattern dystrophies of RPE, etc. in study eye
• severe non-proliferative or worse diabetic retinopathy or diabetic macular edema
in study eye
• other progressive ocular disease that could impair visual acuity such as glaucoma
in the study eye
• lensectomy or intraocular lens implantation within 3 months
Interventions Laser wavelength: dye yellow laser (577 nm) or infrared diode (very early - was discontin-
ued). Number of burns: various, 2 scatter patterns described below; spot size: 50microns;
duration: 0.1 seconds; intensity: very light grey burn (just visible); no treatment within
500 microns of foveal centre and beyond 3000 microns from foveal centre; scatter burns
approximately 2 to 3 burn widths apart, trying to avoid placing burns directly over focal
clumps of hyperpigmentation. Do not have to place directly on drusen, but in placing
scatter, small placement changes (< 50 microns) should be done to centre spot on drusen
Pattern 1) (temporal = 180 degree) - not placed in nasal portion of macula (vertical line
intersects foveal centre)
Pattern 2) (temporal and nasal = 360 degree) - burns placed in scatter both nasal and
temporal portion of macula (exclusive of central macula within 500 microns of foveal
centre and not beyond 3000 microns of foveal centre)
Outcomes Development of CNV, visual acuity; information on other outcomes not available
Notes Randomisation changed - originally 1:1 (laser vs. observation), then laser group ran-
domised (1:1) infrared diode vs. yellow dye - each colour laser was randomised (1:1)
temporal vs. temporal & nasal
The red diode laser arm was stopped early (probably December 1995)
Pilot study nature - so some clinical centres did not do all tests (reading, contrast) - not
all clinical photos graded
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated. Randomly selected
block size (Marta M Gilson personal com-
munication)
Allocation concealment? Yes Serially numbered sealed opaque en-
velopes. Co-ordinator had to fill out check-
list - document eligibility - then open
sequentially numbered envelope, record
date opened, time opened, patient number,
name code, and sign the form, (2 copies -
keep one, and fax other to co-ordinating
centre within 24 hours of opening. Faxed
forms were later mailed to co-ordinating
centre (Marta M Gilson personal commu-
nication)
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Laser to Drusen Study (Continued)
Blinding?
Development of CNV/geographic atrophy
Yes Participants: unclear; care providers: oph-
thalmologists (applying laser) were not
masked; care providers - Co-ordinators:
unclear; outcome assessors: Photograph
Reading Centre graders were to be masked,
but it is possible that some of the laser scars
may have unmasked the graders (Marta M
Gilson personal communication)
Blinding?
Measurement of vision
Unclear Vision acuity examiners: unclear
Incomplete outcome data addressed?
All outcomes
Yes See Results, Appendix 5 and Figure 3. 7/
47 (15%) of treatment group and 10/52
(19%) of control group lost at 2 years. No
information on reasons for loss to follow
up
Free of selective reporting? Yes Outcomes selected by review author
Free of other bias? Unclear Unclear
Little 1995
Methods Method of allocation: after patients eligibility was ascertained and patient consent was
obtained, one eye was randomised to photocoagulation treatment; the right eye was
assigned to treatment if patient’s birth date was an odd month, the left if it was an even
month
Masking: participant: unclear; provider: unclear; outcome assessor: unclear
Exclusions after randomisation:
Losses to follow up: a minimum 1-year follow up was obtained (mean 3.2 years)
Unusual study design (paired study)
Participants Country: USA
Number randomised: 27
Age: mean 69.7
Sex: 9 males/18 females
Inclusion criteria: symmetrical drusen; minimum drusen size 100 micrometre; at least
20 drusen or 10 drusen + 2 drusen at least 500 micrometre in diameter; drusen within
500 micrometre from foveola; VA at least 20/60
Exclusion criteria: PED; atrophy; subretinal fluid, haemorrhage, exudate; any other eye
disorder which could affect VA
Interventions Treatment: 577 to 620 wavelength laser with 100 to 200 micrometre spot size, 0.05 to
0.1 seconds duration, 100 to 200 power. Direct treatment of the drusen
Control: observation
Duration: 1 to 6-year follow up
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Little 1995 (Continued)
Outcomes Snellen VA; colour vision (Farnsworth panel D-15 colour-test); central visual field with
Humphrey 10-2
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No After patients eligibility was ascertained
and patient consent was obtained, one eye
was randomised to photocoagulation treat-
ment; the right eye was assigned to treat-
ment if patient’s birth date was an odd
month, the left if it was an even month
Allocation concealment? No See above, the enrolling researcher could
have foreseen which eye would have been
treated. Nonetheless, this can be irrelevant
since both eyes of each patient were in-
cluded, i.e. there is no risk of confounding
Blinding?
Development of CNV/geographic atrophy
Yes Unmasked study, but CNV occurrence is
sufficiently objective as a diagnosis to be
considered unbiased
Blinding?
Measurement of vision
No Not reported. Patients cannot be masked
since no sham procedure is mentioned
Incomplete outcome data addressed?
All outcomes
Unclear Unclear: only last visit data reported, thus
being impossible to reconstruct the pattern
of missing data; 4 out of 27 patients were
followed for at least 1 year but less than 2
years
Free of selective reporting? Yes Development of CNV and atrophy, as well
as loss of 3 or more lines of visual acuity are
well-defined and relevant outcomes
Free of other bias? Unclear Unclear
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Olk 1999
Methods Method of allocation: not reported; BILATERAL: 1 eye was assigned to treatment and 1
eye to observation.UNILATERAL: 1 eye eligible that eyewas assigned to either treatment
or observation. BILATERAL/UNILATERAL: eyes assigned to treatment were further
randomised to either ’visible’ or ’subthreshold’ treatment
Masking: participant: unclear; provider: unclear; outcome: unclear
Exclusions after randomisation: 25/152 patients (35 eyes) were enrolled initially in the
pilot study but subsequently determined to be ineligible for various reasons, mainly
violation of inclusion criteria
Losses to follow up: at 24 months, 33 eyes had missed visits: 9 eyes (4 observation, 2
visible, 3 subthreshold) were in deceased patients, 14 eyes were in the observation group,
and 10 eyes were in the treatment group (5 eyes, visible; 5 eyes, subthreshold)
Unusual study design: some eyes
Participants Country: USA
Number randomised: BILATERAL: 77 patients (154 eyes) with both eyes eligible UNI-
LATERAL: 75 patients (75 eyes) with 1 eye eligible (unilateral study arm), that eye was
assigned to either treatment or observation
Sex: of 152 patients enrolled; 57 males, 95 females
Age: mean 74.5, range of 54 to 88 years
Inclusion criteria: age older than 50 years; diagnosis of AMD with at least 5 large (63
µm or more), soft drusen within 2250 µm of the centre of the foveal avascular zone in
both eyes (bilateral study arm) or in one eye (unilateral study arm) if the fellow eye had
evidence of exudative AMD; and VA of 20/63 or greater on the ETDRS chart in all
eligible eyes
Exclusion criteria: exudative macular degeneration in either eye for bilateral patients and
in both eyes for unilateral patients; other ocular diseases
Interventions Eyes were treated with a slit-lamp integrated diode photocoagulator using 810-nm wave-
length (IRIS Medical OcuLight SLx; IRIDEX Corp., Mt. View, CA). 48 diode laser
lesions of 125 mm were applied in 4 concentric circles outside the FAZ in a scatter or
grid pattern between 750 mm and 2250 mm from the centre of the fovea. Test spot laser
lesions were applied to the retina nasal to the optic nerve using 200-msec duration, and
the power was increased to produce a mild grey lesion (visible burn). For eyes assigned
to visible treatment, this intensity was then applied in a grid pattern as described above.
For eyes assigned to subthreshold treatment, the energy needed for the visible test burn
was kept constant, but the duration was halved to 100 msec and treatment then carried
out. Only one laser treatment was applied to each eye throughout the duration of the
study
Outcomes Anatomic: reduction of drusen, development of CNV. Functional: visual acuity
Notes Within-patient correlation of outcomes in the bilateral arm not analysed and reported
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
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Olk 1999 (Continued)
Allocation concealment? Unclear Not reported
Blinding?
Development of CNV/geographic atrophy
Yes Unmasked study, but CNV occurrence is
sufficiently objective as a diagnosis to be
considered unbiased
Blinding?
Measurement of vision
No Not reported. Patients cannot be masked
since no sham procedure is mentioned
Incomplete outcome data addressed?
All outcomes
No See Results, Appendix 5 and Figure 3.
Losses to follow up: at 24 months, 33 eyes
had missed visits: 9 eyes (4 observation, 2
visible, 3 subthreshold) were in deceased
patients, 14 eyes were in the observation
group, and 10 eyes were in the treatment
group (5 eyes, visible; 5 eyes, subthreshold).
Causes of loss to follow up other than death
are not reported
Free of selective reporting? Yes Development of CNV and atrophy, as well
as loss of 3 or more lines of visual acuity are
well-defined and relevant outcomes
Free of other bias? Unclear Unclear
PTAMD
Methods Method of allocation: study eyes were assigned randomly to either treatment or observa-
tion by a computer-generated, centre-specific, variable block size randomisation at a 1:1
ratio. These random assignments were concealed in opaque envelopes that were opened
only upon enrolment of an eligible patient who gave consent
Masking: participant: unclear; provider: unclear; outcome: unclear
Exclusions after randomisation: not reported
Losses to follow up: at 1 year 184/244 (75%) patients followed (5 deaths), 92 treated eyes
and 99 control eyes followed. At 3 years 124/244 (51%) patients followed (20 deaths),
64 treated eyes and 55 control eyes followed
Unusual study design: another arm of the study included patients with both eyes eligible,
but this report deals with unilateral patients only
Participants Country: USA
Number randomised: 244
Age: mean 75.4 treated patients, 75.1 observed patients
Gender: (% female) 59.3 treated patients, 61.5 observed patients
Inclusion criteria: age 50 or more. Eligible eye must have BCVA of at least 20/63 on the
ETDRS chart; AMD with at least 5 drusen that are 63 µm in diameter and are located
within 2250 µm of the centre of the fovea; unilateral participants must have one eye
ineligible due to vision loss that is attributed to advanced AMD
Exclusion criteria: other ocular disease causing visual loss
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PTAMD (Continued)
Interventions Eyes randomised to treatment received a single-session treatment of a grid of 48 diode
laser lesions of 125 micrometre in diameter. Laser treatment was applied in an annular
grid that extended from 0.5 (750 micrometre) to 2.0 (3000 micrometre) disc diameters
from the centre of the foveal avascular zone. A slit lamp-based diode laser photocoagu-
lation system (IRIS Medical, Mountain View, CA) emitting energy at 810 nm was used
to deliver the laser treatment. Laser lesions were placed in a subthreshold manner by
first delivering test spot(s) of 200-millisecond duration placed outside of the macula at
a low power (e.g. 200 mW) and then incrementally increasing the power in small (50
mW) increments until a faint grey (threshold) lesion could be detected visually through
the treatment lens. While the power setting was left unchanged, the pulse duration was
reduced to a 100-millisecond interval to achieve an invisible subthreshold lesion. Laser
lesions were then scattered within the annular grid as defined above, beginning by placing
12 spots in a given quadrant and then proceeding to adjacent quadrants to complete the
treatment pattern. The drusen were not targeted specifically or preferentially. If a visible
lesion was produced while the annular grid treatment was performed, the power setting
was reduced to achieve subthreshold lesions with the remainder
Outcomes Anatomic: drusen reduction, development of CNV. Functional: visual acuity
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated, centre-specific, vari-
able block size randomisation
Allocation concealment? Yes Random assignments were concealed in
opaque envelopes that were opened only
upon enrolment of an eligible patient who
gave consent
Blinding?
Development of CNV/geographic atrophy
Yes Unmasked study, but CNV occurrence is
sufficiently objective as a diagnosis to be
considered unbiased
Blinding?
Measurement of vision
Unclear Not reported, masking
of care providers and photograph graders
might be achieved since subthreshold pho-
tocoagulation should not generate visible
scars. Patients cannot be masked since no
sham procedure is mentioned
Incomplete outcome data addressed?
All outcomes
No See Results, Appendix 5 and Figure 3. Sur-
vival analysis used. Losses to follow up: at
1 year 184/244 (75%) patients followed (5
deaths), 92 treated eyes and 99 control eyes
followed. At 3 years 124/244 (51%) pa-
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PTAMD (Continued)
tients followed (20 deaths), 64 treated eyes
and 55 control eyes followed. Causes of loss
other than death are not reported
Free of selective reporting? Yes Development of CNV and atrophy, as well
as loss of 3 or more lines of visual acuity are
well-defined and relevant outcomes
Free of other bias? Unclear Unclear
AMD: age-related macular degeneration
AREDS: Age-related Eye Disease Study
BCVA: best-corrected visual acuity
CNV: choroidal neovascularisation
ETDRS: Early Treatment Diabetic Retinopathy Study
FAZ: foveal avascular zone
MPS: Macular Photocoagulation Study
PED: pigment epithelial detachment
RPE: retinal pigment epithelial
VA: visual acuity
vs.: versus
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Sarks 1999 Comparative study but no randomisation
Sigelman 1991 Case report
Characteristics of studies awaiting assessment [ordered by study ID]
Sivagnanavel 2004
Methods Prospective, double masked, randomised controlled trial at King’s College Hospital, London
Participants Patients with subfoveal choroidal neovascularisation (CNV) from age-related macular degeneration (AMD) in one
eye and significant drusen (> 5 large drusen or > 20 small drusen) in the fellow eye
Interventions Drusen photocoagulation by means of diode laser using large spot size, low energy and long duration (4200 microns
x 400 mw x 60 s); control group received sham treatment (laser with no energy)
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Sivagnanavel 2004 (Continued)
Outcomes Fundus changesmeasured with photography, visual acuity, contrast sensitivity and colour contrast sensitivity recorded
every 3 months
Notes -
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D A T A A N D A N A L Y S E S
Comparison 1. Photocoagulation versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development of CNV 9 3000 Odds Ratio (M-H, Random, 95% CI) 1.04 [0.71, 1.51]
1.1 Bilateral studies 5 2432 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.63, 1.37]
1.2 Unilateral studies 6 568 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.54, 1.84]
2 Development of CNV:
sensitivity analysis assuming
moderate correlation (0.5) for
bilateral studies
9 Odds Ratio (Random, 95% CI) 1.06 [0.72, 1.55]
2.1 Bilateral studies 5 Odds Ratio (Random, 95% CI) 1.08 [0.61, 1.91]
2.2 Unilateral studies 6 Odds Ratio (Random, 95% CI) 1.00 [0.54, 1.84]
3 Development of geographic
atrophy
2 148 Odds Ratio (M-H, Fixed, 95% CI) 1.30 [0.38, 4.51]
4 Visual loss of 2 to 3+ lines 7 Odds Ratio (Random, 95% CI) 0.88 [0.67, 1.14]
4.1 Bilateral studies 3 Odds Ratio (Random, 95% CI) 0.75 [0.54, 1.04]
4.2 Unilateral studies 5 Odds Ratio (Random, 95% CI) 1.17 [0.75, 1.82]
5 Loss of 0.3 or more log units of
contrast sensitivity at 2 years
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6 Reading speed (words/minute) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7 Drusen reduction 2 195 Odds Ratio (IV, Fixed, 95% CI) 10.72 [3.84, 29.97]
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Analysis 1.1. Comparison 1 Photocoagulation versus control, Outcome 1 Development of CNV.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 1 Development of CNV
Study or subgroup Photocoagulation Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Bilateral studies
CAPT 41/1008 50/1008 24.4 % 0.81 [ 0.53, 1.24 ]
DLS 12/103 7/103 10.5 % 1.81 [ 0.68, 4.80 ]
Figueroa 1994 0/30 1/30 1.3 % 0.32 [ 0.01, 8.24 ]
Little 1995 3/27 5/27 5.1 % 0.55 [ 0.12, 2.58 ]
Olk 1999 3/31 3/65 4.5 % 2.21 [ 0.42, 11.66 ]
Subtotal (95% CI) 1199 1233 45.7 % 0.93 [ 0.63, 1.37 ]
Total events: 59 (Photocoagulation), 66 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.08, df = 4 (P = 0.40); I2 =2%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Unilateral studies
CNVPT 12/46 13/47 11.4 % 0.92 [ 0.37, 2.31 ]
DLS 27/91 15/85 15.5 % 1.97 [ 0.96, 4.03 ]
Frennesson 1995 0/17 5/19 1.5 % 0.08 [ 0.00, 1.48 ]
Laser to Drusen Study 6/40 11/42 8.7 % 0.50 [ 0.16, 1.51 ]
Olk 1999 4/21 7/26 6.0 % 0.64 [ 0.16, 2.57 ]
PTAMD 13/63 9/71 11.2 % 1.79 [ 0.71, 4.53 ]
Subtotal (95% CI) 278 290 54.3 % 1.00 [ 0.54, 1.84 ]
Total events: 62 (Photocoagulation), 60 (Control)
Heterogeneity: Tau2 = 0.26; Chi2 = 9.44, df = 5 (P = 0.09); I2 =47%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 1477 1523 100.0 % 1.04 [ 0.71, 1.51 ]
Total events: 121 (Photocoagulation), 126 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 14.09, df = 10 (P = 0.17); I2 =29%
Test for overall effect: Z = 0.19 (P = 0.85)
0.01 0.1 1 10 100
Favours photocoagulation Favours control
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Analysis 1.2. Comparison 1 Photocoagulation versus control, Outcome 2 Development of CNV: sensitivity
analysis assuming moderate correlation (0.5) for bilateral studies.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 2 Development of CNV: sensitivity analysis assuming moderate correlation (0.5) for bilateral studies
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Bilateral studies
CAPT -0.22865 (0.152192) 19.5 % 0.80 [ 0.59, 1.07 ]
DLS 0.59249 (0.356873) 12.8 % 1.81 [ 0.90, 3.64 ]
Figueroa 1994 -1.13195 (1.240966) 2.3 % 0.32 [ 0.03, 3.67 ]
Little 1995 -0.59784 (0.563085) 7.9 % 0.55 [ 0.18, 1.66 ]
Olk 1999 0.79493 (0.445526) 10.4 % 2.21 [ 0.92, 5.30 ]
Subtotal (95% CI) 52.8 % 1.08 [ 0.61, 1.91 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 9.91, df = 4 (P = 0.04); I2 =60%
Test for overall effect: Z = 0.27 (P = 0.79)
2 Unilateral studies
CNVPT -0.08004 (0.46806) 9.8 % 0.92 [ 0.37, 2.31 ]
DLS 0.6774 (0.36553) 12.5 % 1.97 [ 0.96, 4.03 ]
Frennesson 1995 -2.58595 (1.51919) 1.6 % 0.08 [ 0.00, 1.48 ]
Laser to Drusen Study -0.6985091 (0.5650182) 7.8 % 0.50 [ 0.16, 1.51 ]
Olk 1999 -0.44839 (0.71015) 5.7 % 0.64 [ 0.16, 2.57 ]
PTAMD 0.58284 (0.47346) 9.7 % 1.79 [ 0.71, 4.53 ]
Subtotal (95% CI) 47.2 % 1.00 [ 0.54, 1.84 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 9.37, df = 5 (P = 0.10); I2 =47%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 100.0 % 1.06 [ 0.72, 1.55 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 19.95, df = 10 (P = 0.03); I2 =50%
Test for overall effect: Z = 0.27 (P = 0.78)
0.01 0.1 1 10 100
Favours photocoagulation Favours control
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Analysis 1.3. Comparison 1 Photocoagulation versus control, Outcome 3 Development of geographic
atrophy.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 3 Development of geographic atrophy
Study or subgroup Photocoagulation Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CNVPT 5/32 3/34 56.3 % 1.91 [ 0.42, 8.76 ]
Laser to Drusen Study 1/40 2/42 43.7 % 0.51 [ 0.04, 5.89 ]
Total (95% CI) 72 76 100.0 % 1.30 [ 0.38, 4.51 ]
Total events: 6 (Photocoagulation), 5 (Control)
Heterogeneity: Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.4. Comparison 1 Photocoagulation versus control, Outcome 4 Visual loss of 2 to 3+ lines.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 4 Visual loss of 2 to 3+ lines
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Bilateral studies
CAPT -0.2691125 (0.1748489) 58.8 % 0.76 [ 0.54, 1.08 ]
DLS -0.573346 (0.67029815) 4.0 % 0.56 [ 0.15, 2.10 ]
Figueroa 1994 -0.3254224 (0.99673272) 1.8 % 0.72 [ 0.10, 5.09 ]
Subtotal (95% CI) 64.6 % 0.75 [ 0.54, 1.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.083)
2 Unilateral studies
CNVPT -0.2772899 (0.5531024) 5.9 % 0.76 [ 0.26, 2.24 ]
DLS 0.4986213 (0.4032875) 11.1 % 1.65 [ 0.75, 3.63 ]
Laser to Drusen Study -0.1957446 (0.7104946) 3.6 % 0.82 [ 0.20, 3.31 ]
Olk 1999 -0.238411 (0.5902647) 5.2 % 0.79 [ 0.25, 2.51 ]
PTAMD 0.3746934 (0.4297128) 9.7 % 1.45 [ 0.63, 3.38 ]
Subtotal (95% CI) 35.4 % 1.17 [ 0.75, 1.82 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.29, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 100.0 % 0.88 [ 0.67, 1.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.03, df = 7 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
0.1 0.2 0.5 1 2 5 10
Favours photocoagulation Favours control
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Analysis 1.5. Comparison 1 Photocoagulation versus control, Outcome 5 Loss of 0.3 or more log units of
contrast sensitivity at 2 years.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 5 Loss of 0.3 or more log units of contrast sensitivity at 2 years
Study or subgroup Photocoagulation Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Laser to Drusen Study 4/40 5/42 0.82 [ 0.20, 3.31 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (Photocoagulation), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.6. Comparison 1 Photocoagulation versus control, Outcome 6 Reading speed (words/minute).
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 6 Reading speed (words/minute)
Study or subgroup Photocoagulation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Laser to Drusen Study 20 112.2 (28.8) 24 99.7 (37.8) 12.50 [ -7.20, 32.20 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-100 -50 0 50 100
Favours observation Favours photocoagulation
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Analysis 1.7. Comparison 1 Photocoagulation versus control, Outcome 7 Drusen reduction.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 7 Drusen reduction
Study or subgroup Photocoagulation Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
CNVPT 25/30 14/31 74.3 % 6.07 [ 1.84, 20.01 ]
PTAMD 40/79 1/55 25.7 % 55.38 [ 7.30, 420.27 ]
Total (95% CI) 109 86 100.0 % 10.72 [ 3.84, 29.97 ]
Total events: 65 (Photocoagulation), 15 (Control)
Heterogeneity: Chi2 = 3.40, df = 1 (P = 0.07); I2 =71%
Test for overall effect: Z = 4.52 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours photocoagulation
A D D I T I O N A L T A B L E S
Table 1. Primary analysis data including deaths and missing cases
Study Photocoagulation Observation Risk of bias due to incomplete outcome data
F S D M F S D M
CAPT 41 967 25 19 50 958 25 19 Low
CNVPT 12 34 2 11 13 34 3 11 Low
DLS bilat-
eral
12 91 0 2 7 96 0 2 Low
DLS uni-
lateral
27 72 0 0 15 70 0 0 Low
Figueroa
1994
0 30 0 0 1 29 0 0 Low
Frennes-
son
1995
0 17 0 2 4 15 0 0 Low
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Table 1. Primary analysis data including deaths and missing cases (Continued)
Laser
to Drusen
Study
6 34 0 7 11 31 0 10 Low
Little 1995
1
3 24 NA NA 5 22 NA NA Unclear
Olk 1999
bilateral
3 28 2 10 3 62 4 5 High
Olk 1999
unilateral2
4 17 NA 6 7 19 NA 4 High
PTAMD3 13 50 5.5 55.5 9 62 5.5 43.5 High
The assessment of the risk of bias due to incomplete outcome data is based on the graphical presentation in Figure 3 based on the
methods described in Appendix 5.
F: failures (CNV development), S: successes, D: deaths, M: missing of unknown cause, NA: not available.
1Only last visit follow up available and no information on when CV developed in cases with event.
2Deaths are not reported and all missing data were coded as missing of unknown cause.
3Deaths were provided overall (n = 11 at 2 years) and were equally split between assignment groups. Data at 1 or 3 years are available
and midpoints were used.
Table 2. Characteristics of the intervention and control in each study
Study ID Laser type Parameters Control
PTAMD Diode 125 µm spot size/0.1 sec/grid of 48 le-
sions
Observation
DLS Argon green/yellow dye 200 µm spot size/0.2 sec/12 burns Observation
Little 1995 Dye 577 to 620 nm 100 to 200 µm spot size/ 0.05 to 0.1
sec
Observation
Olk 1999 Diode 125 µm spot size/0.2 sec/grid of 48
burns
Observation
CNVPT Argon 100 µm spot size/0.1 sec/ laser-20 pro-
tocol in 85% of cases
Observation
Frennesson 1995 Argon 200 µm spot size/0.05 sec/temporal
horseshoe-shaped area
Observation
Figueroa 1994 Argon 100 µm spot size/0.1 sec/ temporal
fovea or grid pattern
Observation
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Table 2. Characteristics of the intervention and control in each study (Continued)
CAPT Argon 100 µm spot size/0.1 sec/60 burns Observation
Laser to Drusen Study Yellow dye 50 µm spot size/0.1 sec/variable num-
ber
Observation
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Retinal Drusen
#2 drusen*
#3 (#1 OR #2)
#4 MeSH descriptor Lasers
#5 laser*
#6 MeSH descriptor Laser Coagulation
#7 photocoagulat*
#8 (#4 OR #5 OR #6 OR #7)
#9 (#3 AND #8)
Appendix 2. MEDLINE search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp retinal drusen/
14. drusen$.tw.
15. or/13-14
16. exp lasers/
17. laser$.tw.
18. exp laser coagulation/
19. photocoagulat$.tw.
20. or/16-19
21. 13 and 20
22. 12 and 21
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
50Laser treatment of drusen to prevent progression to advanced age-related macular degeneration (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 3. EMBASE search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp drusen/
34. drusen$.tw.
35. or/33-34
36. exp laser/
37. laser$.tw.
38. exp laser coagulation/
39. photocoagulat$.tw.
40. or/36-39
41. 35 and 40
42. 32 and 41
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Appendix 4. Estimate of the correlation coefficient of the measurements within patients in bilateral
studies
Elbourne 2002 provides a method for conducting meta-analyses of studies using paired data, such as cross-over studies or studies on
paired organs. In this appendix we show how we adjusted the marginal measurements, i.e. with eyes as the unit of analysis extracted
from bilateral studies by the intraindividual correlation coefficient extracted from other studies in order to obtain correct standard
errors of the odds ratio.
We found both marginal and paired analyses in DLS. Data were limited to the primary outcome ’development of CNV’ and to the
secondary outcome ’loss of visual acuity’. In particular, Table 4 in DLS presented marginal data on CNV occurrence, our primary
outcome - and visual loss while displaying P values obtained with the McNemar test, which is based on the Chi2 distribution and is
adequate for paired data. In particular, 12/103 laser-treated eyes and 7/103 fellow eyes developed CNV and the McNemar P value was
0.2253. The marginal P value using the Chi2 test would have been 0.2286. We considered that the ratio of the z-values corresponding
to these paired and marginal P values (1.2039 and 1.1907, respectively) could be used to adjust the standard errors of the marginal
logOR of CNV occurrence for laser-treated eyes compared to controls. The inverse ratio of these two z-values is 0.9782, implying that
no adjustment of the marginal logOR standard error is needed for the DLS data. Because the marginal logOR variance is 0.4976, its
value adjusted for the correlation between eyes is 0.4867, the difference between the two being twice the covariance (which is 0.0054).
From these data the correlation coefficient can be calculated to be only 0.0451 (i.e. 0.0054*square root(12*7*96*91)/103), using the
method shown in Elbourne 2002). An issue concerning this correlation coefficient imputation is whether the coverage achieved by the
McNemar test is acceptable given the possibility of cells with counts close to nil in paired 2x2 tables from medium size studies such as
this when events are not common.
Given the negligible effect of the correlation between eyes of the same patient for the CNV development outcome in DLS, we used
marginal data from bilateral studies as if eyes were independent units.
Using the same method for visual acuity loss, the ratio of the marginal and paired logOR standard errors is 0.8143, resulting in a
correlation coefficient of 0.2290. Therefore, for this outcome we decided to use the inverse variance method and adjust the marginal
logOR standard error by 1.2280 (the reciprocal of the previous ratio).
A different estimate of the correlation between eyes for the CNV outcome was obtained from Little 1995. Using the formulas provided
by Elbourne 2002 the correlation coefficient was 0.69 in this small dataset using the last follow up examination to assess the risk of
CNV occurrence. Using Elbourne 2002 notations, the number to calculate this value would be: s = 23, t = 2, u = 0, v = 2, hence a =
25, b = 23, c = 2, d = 4. However, this was a very small study and is expected to estimate correlation imprecisely and also to be affected
by approximations due to low cell counts, for which common formulas for 2x2 tables do not hold. Thus, we did not use this type of
estimate of the correlation coefficient.
Finally, we decided to conduct a sensitivity analysis for the outcome ’development of CNV’ using a moderate correlation between eyes
of 0.5 to correct standard errors of the marginal OR.
Appendix 5. Methods used to deal with incomplete outcome data
We used the following approaches to take into account the impact of missing data. We conducted and reported these calculations on
the odds scale because this was the association measure used in this review, which pooled parallel arm and paired studies.
Method 1
This method aimed at assessing the risk of bias in each study using a forest plot of complete case versus imputed treatment ORs under
extreme, but controlled, assumptions. We considered that the missing condition might act as a modifier of the control event rate and/
or the treatment effect. Modelling these dimensions implies a response to the following questions:
1. Is the control event rate different for missing versus complete patients? As an example, people at larger or smaller risk of CNV
may have been loss to follow up. In this case the OR of event among missing versus complete controls is modelled.
2. Is the control event rate modification different for missing versus complete cases? A relative OR as a multiplier of the observed
OR of treatment for observed patients is modelled and applied to the imputed control event odds.
These methods were applied both to unilateral and bilateral studies, since in our primary analysis we estimated a negligible correlation
within patient (Appendix 4).
We imputed the dataset using the nine combinations obtained from the crossing of 0.5, 1 and 2 for each of the two modifying ORs.
Then we plotted the minimum and maximum OR estimate in a forest plot together with the complete case OR estimate. The resulting
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OR change is assessed graphically and subjectively taking into account its 95% CI to discuss the risk of bias in the primary analysis of
this review, i.e. considering the main conclusion (in this case equivalence of treatment and observation)
Finally, we considered that deaths were unrelated to treatment and we applied the complete case 2x2 probabilities, after dividing the
number of dead patients in each arm by 2, since the a reasonable assumption is that the average observation time before death was the
midpoint of the follow up. Because death was rare in this study we expected very little impact of death on missing imputation. We also
suggest that any other reported cause of missingness believed to be unrelated to treatment may be treated like death, i.e. using the same
probability distribution of the complete cases (however using the entire number of unrelated missing patients for imputation as they
are presumed to be alive). However, there were no cases with reported and unrelated causes of missingness in this review.
As a final comment toMethod 1, we observe that no uncertainty is taken into account with respect tomore formalmethods implemented
in ’metamiss’ as used in Method 2. However, we observe that the assumptions on the Informative Missing Odds Ratio (IMOR), which
are subjective or motivated by context knowledge, are the key determinant of these analyses. Method 1 may be complementary because
it generates graphs for subjective assessment of risk of bias in each study without use of statistical software packages.
Method 2
We used Stata 10.2 software (StataCorp, College Station, Tx) users’ written function ’metamiss’ assuming random uncorrelated opposite
IMORs for treatment and controls (1/2 and 2; 2 and 1/2), which is not far fromwhat was assumed inMethod 1.We assumed additional
uncertainty about log(IMOR) by setting its prior standard deviation at 1, which will result in larger 95% CIs and, finally, in less weight
on studies with a lot of missing data. Finally, we assumed uncorrelated IMORs of treatment and control groups when setting the
’metamiss’ command. The underlying theory and a link to download ’metamiss’ are provided in White 2008.
The results of these sensitivity meta-analyses on the primary analysis occurrence of CNV are shown and discussed.
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